

X William Yang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8955198/publications.pdf>

Version: 2024-02-01

71
papers

7,925
citations

71061

41
h-index

91828

69
g-index

77
all docs

77
docs citations

77
times ranked

10766
citing authors

#	ARTICLE	IF	CITATIONS
1	Full-Length Human Mutant Huntingtin with a Stable Polyglutamine Repeat Can Elicit Progressive and Selective Neuropathogenesis in BACHD Mice. <i>Journal of Neuroscience</i> , 2008, 28, 6182-6195.	1.7	558
2	The mouse cortico-striatal projectome. <i>Nature Neuroscience</i> , 2016, 19, 1100-1114.	7.1	412
3	FACS-array profiling of striatal projection neuron subtypes in juvenile and adult mouse brains. <i>Nature Neuroscience</i> , 2006, 9, 443-452.	7.1	396
4	Integrated genomics and proteomics define huntingtin CAG lengthâ€‘dependent networks in mice. <i>Nature Neuroscience</i> , 2016, 19, 623-633.	7.1	342
5	A multimodal cell census and atlas of the mammalian primary motor cortex. <i>Nature</i> , 2021, 598, 86-102.	13.7	316
6	Exogenous and evoked oxytocin restores social behavior in the <i>Cntnap2</i> mouse model of autism. <i>Science Translational Medicine</i> , 2015, 7, 271ra8.	5.8	308
7	Serines 13 and 16 Are Critical Determinants of Full-Length Human Mutant Huntingtin Induced Disease Pathogenesis in HD Mice. <i>Neuron</i> , 2009, 64, 828-840.	3.8	288
8	Systematic behavioral evaluation of Huntington's disease transgenic and knock-in mouse models. <i>Neurobiology of Disease</i> , 2009, 35, 319-336.	2.1	281
9	Network Organization of the Huntingtin Proteomic Interactome in Mammalian Brain. <i>Neuron</i> , 2012, 75, 41-57.	3.8	262
10	Elevated TREM2 Gene Dosage Reprograms Microglia Responsivity and Ameliorates Pathological Phenotypes in Alzheimerâ€™s Disease Models. <i>Neuron</i> , 2018, 97, 1032-1048.e5.	3.8	246
11	Assembly and Function of Heterotypic Ubiquitin Chains in Cell-Cycle and Protein Quality Control. <i>Cell</i> , 2017, 171, 918-933.e20.	13.5	245
12	Pathological Cell-Cell Interactions Elicited by a Neuropathogenic Form of Mutant Huntingtin Contribute to Cortical Pathogenesis in HD Mice. <i>Neuron</i> , 2005, 46, 433-444.	3.8	222
13	Conditions and Constraints for Astrocyte Calcium Signaling in the Hippocampal Mossy Fiber Pathway. <i>Neuron</i> , 2014, 82, 413-429.	3.8	206
14	Huntington's disease accelerates epigenetic aging of human brain and disrupts DNA methylation levels. <i>Aging</i> , 2016, 8, 1485-1512.	1.4	192
15	Striatal neurons directly converted from Huntingtonâ€™s disease patient fibroblasts recapitulate age-associated disease phenotypes. <i>Nature Neuroscience</i> , 2018, 21, 341-352.	7.1	186
16	Morphological diversity of single neurons in molecularly defined cell types. <i>Nature</i> , 2021, 598, 174-181.	13.7	180
17	Identifying polyglutamine protein species in situ that best predict neurodegeneration. <i>Nature Chemical Biology</i> , 2011, 7, 925-934.	3.9	178
18	Neuronal targets for reducing mutant huntingtin expression to ameliorate disease in a mouse model of Huntington's disease. <i>Nature Medicine</i> , 2014, 20, 536-541.	15.2	177

#	ARTICLE	IF	CITATIONS
19	DNA hypomethylation restricted to the murine forebrain induces cortical degeneration and impairs postnatal neuronal maturation. <i>Human Molecular Genetics</i> , 2009, 18, 2875-2888.	1.4	169
20	Bacterial Artificial Chromosome Transgenic Mice Expressing a Truncated Mutant Parkin Exhibit Age-Dependent Hypokinetic Motor Deficits, Dopaminergic Neuron Degeneration, and Accumulation of Proteinase K-Resistant I \pm -Synuclein. <i>Journal of Neuroscience</i> , 2009, 29, 1962-1976.	1.7	168
21	Deletion of Astroglial Dicer Causes Non-Cell-Autonomous Neuronal Dysfunction and Degeneration. <i>Journal of Neuroscience</i> , 2011, 31, 8306-8319.	1.7	154
22	An Antisense CAG Repeat Transcript at JPH3 Locus Mediates Expanded Polyglutamine Protein Toxicity in Huntington's Disease-like 2 Mice. <i>Neuron</i> , 2011, 70, 427-440.	3.8	127
23	The mouse cortico-basal ganglia-thalamic network. <i>Nature</i> , 2021, 598, 188-194.	13.7	126
24	Differential Electrophysiological Changes in Striatal Output Neurons in Huntington's Disease. <i>Journal of Neuroscience</i> , 2011, 31, 1170-1182.	1.7	125
25	Targeted expression of μ -opioid receptors in a subset of striatal direct-pathway neurons restores opiate reward. <i>Nature Neuroscience</i> , 2014, 17, 254-261.	7.1	118
26	Cellular anatomy of the mouse primary motor cortex. <i>Nature</i> , 2021, 598, 159-166.	13.7	117
27	Targeting ATM ameliorates mutant Huntingtin toxicity in cell and animal models of Huntington's disease. <i>Science Translational Medicine</i> , 2014, 6, 268ra178.	5.8	103
28	Full-length huntingtin levels modulate body weight by influencing insulin-like growth factor 1 expression. <i>Human Molecular Genetics</i> , 2010, 19, 1528-1538.	1.4	100
29	Cleavage at the 586 Amino Acid Caspase-6 Site in Mutant huntingtin Influences Caspase-6 Activation <i>In Vivo</i> . <i>Journal of Neuroscience</i> , 2010, 30, 15019-15029.	1.7	94
30	A fully humanized transgenic mouse model of Huntington disease. <i>Human Molecular Genetics</i> , 2013, 22, 18-34.	1.4	93
31	A Novel BACHD Transgenic Rat Exhibits Characteristic Neuropathological Features of Huntington Disease. <i>Journal of Neuroscience</i> , 2012, 32, 15426-15438.	1.7	89
32	Dopamine modulation of excitatory currents in the striatum is dictated by the expression of D1 or D2 receptors and modified by endocannabinoids. <i>European Journal of Neuroscience</i> , 2010, 31, 14-28.	1.2	87
33	Genetic control of instrumental conditioning by striatopallidal neuron-specific S1P receptor Cpr6. <i>Nature Neuroscience</i> , 2007, 10, 1395-1397.	7.1	80
34	Pivotal role of early B-cell factor 1 in development of striatonigral medium spiny neurons in the matrix compartment. <i>Journal of Neuroscience Research</i> , 2008, 86, 2134-2146.	1.3	75
35	N17 Modifies Mutant Huntingtin Nuclear Pathogenesis and Severity of Disease in HD BAC Transgenic Mice. <i>Neuron</i> , 2015, 85, 726-741.	3.8	66
36	Cortical Efferents Lacking Mutant huntingtin Improve Striatal Neuronal Activity and Behavior in a Conditional Mouse Model of Huntington's Disease. <i>Journal of Neuroscience</i> , 2015, 35, 4440-4451.	1.7	58

#	ARTICLE	IF	CITATIONS
37	Genetic manipulations of mutant huntingtin in mice: new insights into Huntington's disease pathogenesis. <i>FEBS Journal</i> , 2013, 280, 4382-4394.	2.2	53
38	“Huntingtin Holiday” Progress toward an Antisense Therapy for Huntington's Disease. <i>Neuron</i> , 2012, 74, 964-966.	3.8	52
39	An Overview on the Generation of BAC Transgenic Mice for Neuroscience Research. <i>Current Protocols in Neuroscience</i> , 2005, 31, Unit 5.20.	2.6	48
40	P2X4 Receptor Reporter Mice: Sparse Brain Expression and Feeding-Related Presynaptic Facilitation in the Arcuate Nucleus. <i>Journal of Neuroscience</i> , 2016, 36, 8902-8920.	1.7	47
41	Caspase-6 Activity in a BACHD Mouse Modulates Steady-State Levels of Mutant Huntingtin Protein But Is Not Necessary for Production of a 586 Amino Acid Proteolytic Fragment. <i>Journal of Neuroscience</i> , 2012, 32, 7454-7465.	1.7	46
42	DNA methylation study of Huntington’s disease and motor progression in patients and in animal models. <i>Nature Communications</i> , 2020, 11, 4529.	5.8	45
43	Castration delays epigenetic aging and feminizes DNA methylation at androgen-regulated loci. <i>ELife</i> , 2021, 10, .	2.8	45
44	The N17 domain mitigates nuclear toxicity in a novel zebrafish Huntington’s disease model. <i>Molecular Neurodegeneration</i> , 2015, 10, 67.	4.4	44
45	Serine 421 regulates mutant huntingtin toxicity and clearance in mice. <i>Journal of Clinical Investigation</i> , 2016, 126, 3585-3597.	3.9	44
46	Molecular insights into cortico-striatal miscommunications in Huntington's disease. <i>Current Opinion in Neurobiology</i> , 2018, 48, 79-89.	2.0	43
47	MicroRNA signatures of endogenous Huntingtin CAG repeat expansion in mice. <i>PLoS ONE</i> , 2018, 13, e0190550.	1.1	39
48	A novel humanized mouse model of Huntington disease for preclinical development of therapeutics targeting mutant huntingtin alleles. <i>Human Molecular Genetics</i> , 2017, 26, ddx021.	1.4	37
49	Brainwide Genetic Sparse Cell Labeling to Illuminate the Morphology of Neurons and Glia with Cre-Dependent MORF Mice. <i>Neuron</i> , 2020, 108, 111-127.e6.	3.8	37
50	Enhanced mitochondrial biogenesis ameliorates disease phenotype in a full-length mouse model of Huntington’s disease. <i>Human Molecular Genetics</i> , 2016, 25, 2269-2282.	1.4	35
51	Molecular and cellular basis of obsessive-compulsive disorder-like behaviors: emerging view from mouse models. <i>Current Opinion in Neurology</i> , 2011, 24, 114-118.	1.8	32
52	Uninterrupted CAG repeat drives striatum-selective transcriptionopathy and nuclear pathogenesis in human Huntington BAC mice. <i>Neuron</i> , 2022, 110, 1173-1192.e7.	3.8	30
53	Precise segmentation of densely interweaving neuron clusters using G-Cut. <i>Nature Communications</i> , 2019, 10, 1549.	5.8	28
54	PIAS1 modulates striatal transcription, DNA damage repair, and SUMOylation with relevance to Huntington’s disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	28

#	ARTICLE	IF	CITATIONS
55	Dangerous duet: LRRK2 and α -synuclein jam at CMA. <i>Nature Neuroscience</i> , 2013, 16, 375-377.	7.1	23
56	Genetically-directed Sparse Neuronal Labeling in BAC Transgenic Mice through Mononucleotide Repeat Frameshift. <i>Scientific Reports</i> , 2017, 7, 43915.	1.6	23
57	Huntington's Disease: Nuclear Gatekeepers Under Attack. <i>Neuron</i> , 2017, 94, 1-4.	3.8	20
58	Flipping a switch on huntingtin. <i>Nature Chemical Biology</i> , 2011, 7, 412-414.	3.9	18
59	Clinical and Genetic Profiles in Chinese Patients with Huntington's Disease: A Ten-year Multicenter Study in China. , 2019, 10, 1003.		16
60	Dosage sensitivity intolerance of VIPR2 microduplication is disease causative to manifest schizophrenia-like phenotypes in a novel BAC transgenic mouse model. <i>Molecular Psychiatry</i> , 2019, 24, 1884-1901.	4.1	14
61	Huntington Disease's Glial Progenitor Cells Hit the Pause Button in the Mouse Brain. <i>Cell Stem Cell</i> , 2019, 24, 3-4.	5.2	14
62	CPEB alteration and aberrant transcriptome-polyadenylation lead to a treatable SLC19A3 deficiency in Huntington's disease. <i>Science Translational Medicine</i> , 2021, 13, eabe7104.	5.8	14
63	Disease-related Huntingtin seeding activities in cerebrospinal fluids of Huntington's disease patients. <i>Scientific Reports</i> , 2020, 10, 20295.	1.6	10
64	An Independent Study of the Preclinical Efficacy of C2-8 in the R6/2 Transgenic Mouse Model of Huntington's Disease. <i>Journal of Huntington's Disease</i> , 2013, 2, 443-451.	0.9	9
65	Life and death rest on a bivalent chromatin state. <i>Nature Neuroscience</i> , 2016, 19, 1271-1273.	7.1	4
66	CLEARance wars: PolyQ strikes back. <i>Nature Neuroscience</i> , 2014, 17, 1140-1142.	7.1	3
67	Probing the stress and depression circuits with a disease gene. <i>ELife</i> , 2015, 4, .	2.8	3
68	Huntington's Disease: Genome-wide Neuroprotection Screening Goes Viral. <i>Neuron</i> , 2020, 106, 4-6.	3.8	1
69	Group dynamics goes awry: PolyQ-expanded huntingtin gains unwanted partners. <i>Cell Systems</i> , 2022, 13, 268-270.	2.9	1
70	Cellular and molecular mechanisms implicated in pathogenesis of selective neurodegeneration in Huntington's disease. <i>Frontiers in Biology</i> , 2012, 7, 459-476.	0.7	0
71	IO3's...CPEB alteration and aberrant transcriptome-polyadenylation unveil a treatable vitamin B1 deficiency in huntington's disease. , 2021, , .		0